「nct」の検索結果

Computes sample size and power for clinical trials including continuous, binary, and time-to-event endpoints; superiority, non-inferiority, and equivalence designs; FDA 2016 non-inferiority margin selection with M1/M2 framework; Schoenfeld 1981 and Lakatos 1988 for survival; Schuirmann TOST and 80-125% bioequivalence; minimum clinically important difference (MCID) vs δ distinction. Use when justifying trial size in protocol or SAP per CONSORT 2025 item 16a.

日本語の概要は準備中です。原文の説明を表示しています。

Implements multiplicity control for confirmatory clinical trials using graphical procedures (Bretz-Maurer-Hommel), gatekeeping (parallel, serial, mixed), Hochberg/Hommel/Holm with PRDS, and the closed-testing principle (Marcus-Peritz-Gabriel; Goeman 2021 admissibility). Covers FDA Multiple Endpoints Final Guidance (October 2022), graphical procedures via R gMCP, primary + key-secondary + subgroup hierarchies, and FWER vs FDR distinction. Use when designing the multiplicity strategy for confirmatory trials with multiple primary or key secondary endpoints.

日本語の概要は準備中です。原文の説明を表示しています。

Treats a ctDNA assay as a molecule-counting experiment at the Poisson edge and builds its analytical-validation case the measurement-science way. Covers the genome-equivalent currency (~330 haploid copies/ng), the lambda = input_GE x VAF sampling ceiling (lambda>=3 for ~95% detection), the error-suppression ladder (raw NGS ~1e-3 -> single-strand UMI ~1e-4/1e-5 -> duplex <1e-7), the CLSI EP17 LoB/LoD/LoD95/LoQ framework, the per-locus-vs-panel-integrated LoD distinction that lets bespoke MRD reach ppm, contrived/SEQC2 reference standards, and honest LoD reporting conditioned on input mass + consensus depth + replicate detection rate. Use when stating or trusting a sensitivity claim, designing a dilution-series validation, deciding how many genome equivalents are needed at a target VAF, choosing a single-locus vs panel-integrated LoD, or auditing a "detects 0.1% VAF" claim.

日本語の概要は準備中です。原文の説明を表示しています。

Detect allele-specific chromatin accessibility from ATAC-seq using WASP, GATK ASEReadCounter, or RASQUAL. Use when mapping cis-regulatory genetic variants from heterozygous SNPs, separating cis from trans regulation, building chromatin QTL (caQTL) maps, validating GWAS variant function with allelic imbalance, or detecting reference allele mapping bias before downstream analysis.

日本語の概要は準備中です。原文の説明を表示しています。

Write articles, guides, blog posts, tutorials, newsletter issues, and other long-form content in a distinctive voice derived from supplied examples or brand guidance. Use when the user wants polished written content longer than a paragraph, especially when voice consistency, structure, and credibility matter.

日本語の概要は準備中です。原文の説明を表示しています。

Suggests initiating inpatient continuous glucose monitoring (CGM) for select hospitalized patients at high risk for hypoglycemia, combined with periodic point-of-care glucose checks for accuracy. Triggers include planning glucose monitoring for inpatients with prior severe hypoglycemia, renal or hepatic dysfunction, or age 65 years or older.

日本語の概要は準備中です。原文の説明を表示しています。

This skill recommends that all patients with Cushing’s syndrome receive monitoring and adjunctive treatment for cortisol-dependent comorbidities including psychiatric disorders, diabetes, hypertension, hypokalemia, infections, dyslipidemia, osteoporosis, and poor physical fitness. Apply when managing any CS patient to address associated health issues; triggers include confirmed or suspected hypercortisolism, preoperative evaluation, postoperative follow‑up, or persistent hypercortisolism despite treatment.

日本語の概要は準備中です。原文の説明を表示しています。

This skill recommends re-evaluating the need for treatment of other pituitary hormone deficiencies in the postoperative period following surgical intervention for Cushing's syndrome. It is triggered when assessing a post-op CS patient for ongoing pituitary function, evaluating for hypopituitarism, or checking HPA axis recovery with morning cortisol/ACTH stimulation tests and pituitary MRI within 1–3 months.

日本語の概要は準備中です。原文の説明を表示しています。

This skill recommends discontinuing glucocorticoid when the response to HPA axis recovery tests (morning cortisol, ACTH stimulation, or insulin-induced hypoglycemia) is normal, indicating adequate adrenal function recovery. Use in postoperative Cushing’s syndrome patients with at least one intact adrenal gland when test results are available.

日本語の概要は準備中です。原文の説明を表示しています。

Determines the appropriate zoledronic acid dose (3‑4 mg IV) and infusion duration based on renal function. Triggered when a clinician prepares to prescribe zoledronic acid for hypercalcemia of malignancy and asks about renal‑adjusted administration.

日本語の概要は準備中です。原文の説明を表示しています。

Recommends initiating intravenous isotonic saline hydration as initial management for hypercalcemia of malignancy (HCM) while awaiting antiresorptive therapy, with fluid rate adjusted according to cardiac function. Triggered when a clinician encounters a patient with HCM (e.g., serum calcium >12 mg/dL, symptoms of hypercalcemia) and seeks immediate measures before specific drugs are available.

日本語の概要は準備中です。原文の説明を表示しています。

Determines when adrenal venous sampling (AVS) is indicated for functional subtyping of primary aldosteronism (PA) when surgical treatment is feasible and desired by the patient. Triggered when a clinician confirms PA diagnosis and asks 'Do I need AVS for subtyping?' or evaluates surgical candidacy.

日本語の概要は準備中です。原文の説明を表示しています。

Advises evaluating creatinine clearance or estimated glomerular filtration rate prior to intravenous bisphosphonate administration to guide dosing and ensure safety. Triggered when a clinician is planning to give zoledronic acid or pamidronate and asks about renal safety checks.

日本語の概要は準備中です。原文の説明を表示しています。

Recommends adding intravenous bisphosphonate or denosumab when hypercalcemia due to parathyroid carcinoma is not adequately controlled with a calcimimetic. Consider this adjunct when a clinician notes persistent HCM despite calcimimetic therapy and asks about next-step therapy.

日本語の概要は準備中です。原文の説明を表示しています。

Remove signs of AI-generated writing from text. Use when editing or reviewing text to make it sound more natural and human-written. Based on Wikipedia's comprehensive "Signs of AI writing" guide. Detects and fixes patterns including: inflated symbolism, promotional language, superficial -ing analyses, vague attributions, em dash overuse, rule of three, AI vocabulary words, negative parallelisms, and excessive conjunctive phrases. Credits: Original skill by @blader - https://github.com/blader/humanizer

日本語の概要は準備中です。原文の説明を表示しています。

Run an org-team workflow — a flat pod of up to four peer Claude Code sessions claims lane-tagged slices of an approved spec over the baseline MCP channel and implements them concurrently, each in its own git worktree. Each peer DECIDES its own in-lane implementation choices in its own main context (Article X); only un-decidable or cross-lane forks escalate peer→lead→human (yield_fork for task-bound forks, ask_lead for free-form queries). Opt-in and OFF by default (velocity.org_mode.enabled). Graduates the retired sprint-dispatch prototype into the constitutionally-sanctioned org-team model (Article X — Multi-session coordinated workflows). Requires git.

日本語の概要は準備中です。原文の説明を表示しています。

Draft a Business Requirements Document (BRD) for cross-functional or stakeholder-heavy work that needs more structure than an intake. Use after `/intake` when the request spans multiple systems/teams, carries regulatory weight, or needs formal sign-off. Output lives at `docs/brd/<slug>.md`.

日本語の概要は準備中です。原文の説明を表示しています。

Propose the next dependency-ready sprint from the ALREADY-DECOMPOSED roadmap — standup's active sibling. Reads docs/roadmap-execution-plan.md + the memory backlog, computes per-task readiness from the roadmap's machine-readable status, orders with roadmap-planner's graph engine, and emits a proposed task-set (sprint-plan manifest shape) with per-feature done-criteria, excluding unready tasks and naming their unmet prerequisite. PROPOSES ONLY — the human confirms/edits before /triage routes it (typically to the `power` track). Distinct from `sprint-plan`, which decomposes a fresh vision.

日本語の概要は準備中です。原文の説明を表示しています。

You MUST use this before any creative work - creating features, building components, adding functionality, or modifying behavior. Explores user intent, requirements and design before implementation.

日本語の概要は準備中です。原文の説明を表示しています。

Drives development with tests. Use when implementing any logic, fixing any bug, or changing any behavior. Use when you need to prove that code works, when a bug report arrives, or when you're about to modify existing functionality.

日本語の概要は準備中です。原文の説明を表示しています。

Design Azure architectures for startups and enterprises. Use when asked to design Azure infrastructure, create Bicep/ARM templates, optimize Azure costs, set up Azure DevOps pipelines, or migrate to Azure. Covers AKS, App Service, Azure Functions, Cosmos DB, and cost optimization.

日本語の概要は準備中です。原文の説明を表示しています。

Specialized skill for building production-ready serverless applications on AWS. Covers Lambda functions, API Gateway, DynamoDB, SQS/SNS event-driven patterns, SAM/CDK deployment, and cold start optimization.

日本語の概要は準備中です。原文の説明を表示しています。

Astropy is the core Python package for astronomy, providing essential functionality for astronomical research and data analysis.

日本語の概要は準備中です。原文の説明を表示しています。

Inter-agent communication protocol for C-suite agent teams. Defines invocation syntax, loop prevention, isolation rules, and response formats. Use when C-suite agents need to query each other, coordinate cross-functional analysis, or run board meetings with multiple agent roles.

日本語の概要は準備中です。原文の説明を表示しています。